A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

被引:36
|
作者
Sun, Wei [1 ]
Six, David [2 ]
Kuang, Xiaoying [1 ]
Roland, Kenneth L. [1 ]
Raetz, Christian R. H. [2 ]
Curtiss, Roy, III [1 ]
机构
[1] Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USA
[2] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
Yersinia pestis; Lipid A; Regulated delayed attenuation; Plague vaccine; RECOMBINANT V-ANTIGEN; ESCHERICHIA-COLI; PNEUMONIC PLAGUE; PROTECTS MICE; MOUSE MODEL; VIRULENCE; IMMUNIZATION; IMMUNITY; GENES; IDENTIFICATION;
D O I
10.1016/j.vaccine.2011.01.099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37 degrees C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37 degrees C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC P-BAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The chi 10030( pCD1Ap) (Delta lpxP32::P-lpxL lpxL Delta P-crp21::TT araC P-BAD crp) construct likewise produced hexa-acylated lipid A at 37 degrees C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was > 10(7)-times and > 10(4)-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6 x 10(7) wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2 x 10(4) live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2986 / 2998
页数:13
相关论文
共 50 条
  • [31] A Recombinant Attenuated Yersinia pseudotuberculosis Vaccine Delivering a Y. pestis YopENt138-LcrV Fusion Elicits Broad Protection against Plague and Yersiniosis in Mice
    Singh, Amit K.
    Curtiss, Roy, III
    Sun, Wei
    INFECTION AND IMMUNITY, 2019, 87 (10)
  • [32] Yersinia pestis (plague) vaccines
    Titball, RW
    Williamson, ED
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (06) : 965 - 973
  • [33] Identification of New Virulence Factors and Vaccine Candidates for Yersinia pestis
    Andersson, Jourdan A.
    Sha, Jian
    Erova, Tatiana E.
    Fitts, Eric C.
    Ponnusamy, Duraisamy
    Kozlova, Elena V.
    Kirtley, Michelle L.
    Chopra, Ashok K.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [34] A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis
    Tao, Pan
    Mahalingam, Marthandan
    Zhu, Jingen
    Moayeri, Mahtab
    Kirtley, Michelle L.
    Fitts, Eric C.
    Andersson, Jourdan A.
    Lawrence, William S.
    Leppla, Stephen H.
    Chopra, Ashok K.
    Rao, Venigalla B.
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [35] Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague
    Goodin, Jeremy L.
    Powell, Bradford S.
    Enama, Jeff T.
    Raab, Ronald W.
    McKown, Robert L.
    Coffman, George L.
    Andrews, Gerard P.
    PROTEIN EXPRESSION AND PURIFICATION, 2011, 76 (01) : 136 - 144
  • [36] The Use of Analgesics during Vaccination with a Live Attenuated Yersinia pestis Vaccine Alters the Resulting Immune Response in Mice
    Culbreth, Marilynn J.
    Biryukov, Sergei S.
    Shoe, Jennifer L.
    Dankmeyer, Jennifer L.
    Hunter, Melissa
    Klimko, Christopher P.
    Rosario-Acevedo, Raysa
    Fetterer, David P.
    Moreau, Alicia M.
    Welkos, Susan L.
    Cote, Christopher K.
    VACCINES, 2019, 7 (04)
  • [37] D27-pLpxL, an Avirulent Strain of Yersinia pestis, Primes T Cells That Protect against Pneumonic Plague
    Szaba, Frank M.
    Kummer, Lawrence W.
    Wilhelm, Lindsey B.
    Lin, Jr-Shiuan
    Parent, Michelle A.
    Montminy-Paquette, Sara W.
    Lien, Egil
    Johnson, Lawrence L.
    Smiley, Stephen T.
    INFECTION AND IMMUNITY, 2009, 77 (10) : 4295 - 4304
  • [38] Research progress on live attenuated vaccine against African swine fever virus
    Liu, Le
    Wang, Xiangwei
    Mao, Ruoqing
    Zhou, Yahua
    Yin, Juanbin
    Sun, Yuefeng
    Yin, Xiangping
    MICROBIAL PATHOGENESIS, 2021, 158
  • [39] Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis
    Bhattacharya, Debaditya
    Mecsas, Joan
    Hu, Linden T.
    VACCINE, 2010, 28 (48) : 7683 - 7689
  • [40] Invasiveness of the Yersinia pestis ail protein contributes to host dissemination in pneumonic and oral plague
    Zhang, Yingmiao
    Ying, Xiaoling
    He, Yingxia
    Jiang, Lingyu
    Zhang, Song
    Bartra, Sara Schesser
    Plano, Gregory, V
    Klena, John D.
    Skurnik, Mikael
    Chen, Hongxiang
    Cai, Huahua
    Chen, Tie
    MICROBIAL PATHOGENESIS, 2020, 141